Castle Biosciences, Inc(NASDAQ:CSTL) 
Castle Biosciences, Inc., a commercial-stage dermatological cancer company, focuses to provide diagnostic and prognostic solutions for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify high-risk patients with stage I and II melano...
Website: http://www.castlebiosciences.com
Founded: 2007
IPO Price: $16 (Jul 25, 2019)
Full Time Employees: 133
CEO: Derek J. Maetzold
Sector: Healthcare
Industry: Diagnostics & Research
The information provided in this report is taken from www.sec.gov. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Day
Week
Month
Date 2025-04-04
P
O 18.51
H 18.99
L 17.91
C 18.57
V 459,518
10EMA 18.57
20EMA 18.57
60EMA 18.57
120EMA 18.57
250EMA 18.57